Arrhythmias induced by silmitasertib (a casein kinase 2 inhibitor) and sunitinib have been reported to result from their effects on RyR2 and increased storage overload-induced Ca2+ release (Figure 1) (Chakraborty et al., 2019). The gene discussed is RYR2; the disease is cardiac arrhythmia.